Biologic response modifiers in gynecologic malignancies.

Por Dutcher, J. P., Wadler, S., Wiernik, P. H.
Publicado em 1988

Serum ferritin concentration in untreated Hodgkin's disease.

Por Jacobs, A., Slater, A., Whittaker, J. A., Canellos, G., Wiernik, P. H.
Publicado em 1976

Lectin activity as a marker for Hodgkin disease cells.

Por Paietta, E, Stockert, R J, Morell, A G, Diehl, V, Wiernik, P H
Publicado em 1986

Unique antigen of cultured Hodgkin's cells. A putative sialyltransferase.

Por Paietta, E, Stockert, R J, Morell, A G, Diehl, V, Wiernik, P H
Publicado em 1986

Restaging laparotomy for Hodgkin's disease.

Por Coker, D D, Morris, D M, Coleman, J J, Wiernik, P H, Elias, E G
Publicado em 1983

Potential of mezlocillin as empiric single-agent therapy in febrile granulocytopenic cancer patients.

Por Wade, J C, Schimpff, S C, Newman, K A, Fortner, C L, Moody, M R, Young, V M, Wiernik, P H
Publicado em 1980

Large and small fibre type sensory dysfunction in patients with cancer.

Por Lipton, R B, Galer, B S, Dutcher, J P, Portenoy, R K, Pahmer, V, Meller, F, Arezzo, J C, Wiernik, P H
Publicado em 1991

Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients.

Por Finley, R S, Fortner, C L, deJongh, C A, Wade, J C, Newman, K A, Caplan, E, Britten, J, Wiernik, P H, Schimpff, S C
Publicado em 1982